Does BROLUCIZUMAB-DBLL Cause Vitreous opacities? 205 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 205 reports of Vitreous opacities have been filed in association with BROLUCIZUMAB-DBLL. This represents 7.3% of all adverse event reports for BROLUCIZUMAB-DBLL.
205
Reports of Vitreous opacities with BROLUCIZUMAB-DBLL
7.3%
of all BROLUCIZUMAB-DBLL reports
1
Deaths
15
Hospitalizations
How Dangerous Is Vitreous opacities From BROLUCIZUMAB-DBLL?
Of the 205 reports, 1 (0.5%) resulted in death, 15 (7.3%) required hospitalization.
Is Vitreous opacities Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BROLUCIZUMAB-DBLL. However, 205 reports have been filed with the FAERS database.
What Other Side Effects Does BROLUCIZUMAB-DBLL Cause?
Vitreous floaters (479)
Visual impairment (446)
Vision blurred (416)
Eye inflammation (387)
Visual acuity reduced (365)
Retinal vasculitis (323)
Uveitis (305)
Vitritis (284)
Eye pain (234)
Anterior chamber cell (199)
What Other Drugs Cause Vitreous opacities?
AFLIBERCEPT (148)
RANIBIZUMAB (58)
METHOTREXATE (19)
FARICIMAB\FARICIMAB-SVOA (17)
BEVACIZUMAB (16)
BROLUCIZUMAB (14)
DEXAMETHASONE (14)
TRIAMCINOLONE ACETONIDE (14)
VENLAFAXINE (11)
FARICIMAB-SVOA (10)
Which BROLUCIZUMAB-DBLL Alternatives Have Lower Vitreous opacities Risk?
BROLUCIZUMAB-DBLL vs BROMAZEPAM
BROLUCIZUMAB-DBLL vs BROMFENAC
BROLUCIZUMAB-DBLL vs BROMHEXINE
BROLUCIZUMAB-DBLL vs BROMOCRIPTINE
BROLUCIZUMAB-DBLL vs BROTIZOLAM